RB Blocking Peptide
Référence MBS9620221-1mg
Conditionnement : 1mg
Marque : MyBiosource
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Rb Blocking Peptide – The purity is >90%,tested by HPLC and MS. Purity
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS9620221Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the… More details
Product Overview
Online Datasheet in PDFProduct Name
RB, Blocking Peptide
Full Product Name
RB Blocking Peptide
Product Gene Name
RB blocking peptide
Product Synonym Names
Exon 17 tumor GOS561 substitution mutation causes premature stop; GOS563 exon 17 substitution mutation causes premature stop; OSRC; Osteosarcoma; p105-Rb; P105RB; PP105; pp110; PPP1R130; pRb; Prepro retinoblastoma associated protein; Protein phosphatase 1 regulatory subunit 130; Rb; RB transcriptional corepressor 1; RB_HUMAN; RB1; RB1 gene; Retinoblastoma 1; Retinoblastoma suspectibility protein; Retinoblastoma-associated protein
Form/Format
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.
Purity/Purification
The purity is >90%,tested by HPLC and MS.
Preparation and Storage
Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.
Antibody/Peptide Pairs
RB peptide (MBS9620221) is used for blocking the activity of RB antibody (MBS9602768)
Molecular Weight
106,159 Da
Chromosome Location
Chromosome: 13; NC_000013.10 (48877883..49056026). Location: 13q14.2
OMIM
109800
Supply Chain Verification
Manufactured in a lab with traceable raw materials manufactured on site. Coordinated product portfolio of antibodies, pairs, conjugates, recombinant proteins, and immunoassay materials available, please inquire.
Notes
For phospho antibody, we provide phospho peptide (0.5mg) and non-phospho peptide (0.5mg)
ISO Certification
Manufactured in an ISO 9001:2015 Certified Laboratory.
Applications Tested/Suitable for RB blocking peptide
Blocking/Control
Related Product Information for RB blocking peptide
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.
Other Notes
Small volumes of RB blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Searchable Terms for RB purchase
MBS9620221 is a blocking peptide targeting RB.
Additional Details
NCBI/Uniprot data below describe general gene information for RB. It may not necessarily be applicable to this product.
NCBI Official Full Name
retinoblastoma-associated protein
NCBI Official Synonym Full Names
retinoblastoma 1
NCBI Official Symbol
RB1
NCBI Official Synonym Symbols
RB; pRb; OSRC; pp110; p105-Rb
UniProt Protein Name
Retinoblastoma-associated protein
UniProt Synonym Protein Names
p105-Rb; pRb; Rb; pp110
Protein Family
RB-associated KRAB zinc finger protein
UniProt Gene Name
RB1
UniProt Synonym Gene Names
Rb
UniProt Entry Name
RB_HUMAN
NCBI Protein Information
retinoblastoma-associated protein; retinoblastoma suspectibility protein
NCBI Summary for RB
The protein encoded by this gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma. [provided by RefSeq, Jul 2008]
Show more UniProt Comments for RB
Rb: retinoblastoma tumor suppressor protein regulates cell proliferation by controlling progression through the G1-phase restriction point. Has three distinct binding domains and interacts with regulatory proteins including the E2F family of transcription factors, c-Abl tyrosine kinase and proteins with a conserved LXCXE motif. Cell cycle-dependent phosphorylation by Cdks inhibits Rb target binding, thus allowing cell cycle progression. Recruits and targets histone methyltransferase suv39h1 leading to epigenetic transcriptional repression.
Protein type: Transcription, coactivator/corepressor; Oncoprotein; Nuclear receptor co-regulator; Tumor suppressor
Chromosomal Location of Human Ortholog: 13q14.2
Cellular Component: nucleoplasm; SWI/SNF complex; PML body; Rb-E2F complex; spindle; chromatin; nucleus
Molecular Function: identical protein binding; protein binding; androgen receptor binding; DNA binding; ubiquitin protein ligase binding; transcription coactivator activity; phosphoprotein binding; kinase binding; transcription factor binding; transcription factor activity
Biological Process: sister chromatid biorientation; viral reproduction; positive regulation of transcription, DNA-dependent; negative regulation of transcription from RNA polymerase II promoter, mitotic; regulation of mitotic cell cycle; neuron maturation; positive regulation of macrophage differentiation; cell cycle arrest; neurite development; negative regulation of epithelial cell proliferation; transcription, DNA-dependent; mitotic cell cycle checkpoint; negative regulation of transcription factor activity; regulation of lipid kinase activity; enucleate erythrocyte differentiation; G1/S-specific transcription in mitotic cell cycle; chromatin remodeling; myoblast differentiation; neuron apoptosis; maintenance of mitotic sister chromatid cohesion; gut development; cell division; neuron morphogenesis during differentiation; negative regulation of smoothened signaling pathway; androgen receptor signaling pathway; Ras protein signal transduction; positive regulation of mitotic metaphase/anaphase transition; negative regulation of protein kinase activity; striated muscle cell differentiation; positive regulation of transcription from RNA polymerase II promoter; mitotic cell cycle; negative regulation of transcription, DNA-dependent; cell cycle checkpoint; G1/S transition of mitotic cell cycle
Disease: Bladder Cancer; Osteogenic Sarcoma; Small Cell Cancer Of The Lung; Retinoblastoma
Show more Protein type: Transcription, coactivator/corepressor; Oncoprotein; Nuclear receptor co-regulator; Tumor suppressor
Chromosomal Location of Human Ortholog: 13q14.2
Cellular Component: nucleoplasm; SWI/SNF complex; PML body; Rb-E2F complex; spindle; chromatin; nucleus
Molecular Function: identical protein binding; protein binding; androgen receptor binding; DNA binding; ubiquitin protein ligase binding; transcription coactivator activity; phosphoprotein binding; kinase binding; transcription factor binding; transcription factor activity
Biological Process: sister chromatid biorientation; viral reproduction; positive regulation of transcription, DNA-dependent; negative regulation of transcription from RNA polymerase II promoter, mitotic; regulation of mitotic cell cycle; neuron maturation; positive regulation of macrophage differentiation; cell cycle arrest; neurite development; negative regulation of epithelial cell proliferation; transcription, DNA-dependent; mitotic cell cycle checkpoint; negative regulation of transcription factor activity; regulation of lipid kinase activity; enucleate erythrocyte differentiation; G1/S-specific transcription in mitotic cell cycle; chromatin remodeling; myoblast differentiation; neuron apoptosis; maintenance of mitotic sister chromatid cohesion; gut development; cell division; neuron morphogenesis during differentiation; negative regulation of smoothened signaling pathway; androgen receptor signaling pathway; Ras protein signal transduction; positive regulation of mitotic metaphase/anaphase transition; negative regulation of protein kinase activity; striated muscle cell differentiation; positive regulation of transcription from RNA polymerase II promoter; mitotic cell cycle; negative regulation of transcription, DNA-dependent; cell cycle checkpoint; G1/S transition of mitotic cell cycle
Disease: Bladder Cancer; Osteogenic Sarcoma; Small Cell Cancer Of The Lung; Retinoblastoma
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with RB blocking peptide
| Reference Product | PubMed Publications |
|---|---|
| JUN blocking peptide | >195 publications with RB and JUN |
| MYC blocking peptide | >93 publications with RB and MYC |
| CCND1 blocking peptide | >86 publications with RB and CCND1 |
| CDK4 blocking peptide | >67 publications with RB and CDK4 |
| MDM2 blocking peptide | >56 publications with RB and MDM2 |
| BRCA1 blocking peptide | >53 publications with RB and BRCA1 |
| CDKN1A blocking peptide | >39 publications with RB and CDKN1A |
| E2F1 blocking peptide | >35 publications with RB and E2F1 |
| RBL1 blocking peptide | >26 publications with RB and RBL1 |
| CASP3 blocking peptide | >24 publications with RB and CASP3 |
Pathways associated with RB blocking peptide
| Products by Pathway | Pathway Diagram |
|---|---|
| Adipogenesis Pathway antibodies | Adipogenesis Pathway Diagram |
| Androgen Receptor Signaling Pathway antibodies | Androgen Receptor Signaling Pathway Diagram |
| B Cell Receptor Signaling Pathway antibodies | B Cell Receptor Signaling Pathway Diagram |
| Bladder Cancer Pathway antibodies | Bladder Cancer Pathway Diagram |
| Bladder Cancer Pathway antibodies | Bladder Cancer Pathway Diagram |
| Cell Cycle Pathway antibodies | Cell Cycle Pathway Diagram |
| Cell Cycle, Mitotic Pathway antibodies | Cell Cycle, Mitotic Pathway Diagram |
| Cell Cycle Pathway antibodies | Cell Cycle Pathway Diagram |
| Cell Cycle Pathway antibodies | Cell Cycle Pathway Diagram |
| Cell Cycle Pathway antibodies | Cell Cycle Pathway Diagram |
Diseases associated with RB blocking peptide
| Disease Name | Pubmed Publications |
|---|---|
| Neoplasms Antibodies | >1158 publications with RB and Neoplasms |
| Retinoblastoma Antibodies | >966 publications with RB and Retinoblastoma |
| Carcinoma Antibodies | >251 publications with RB and Carcinoma |
| Breast Neoplasms Antibodies | >109 publications with RB and Breast Neoplasms |
| Adenocarcinoma Antibodies | >102 publications with RB and Adenocarcinoma |
| Lung Neoplasms Antibodies | >76 publications with RB and Lung Neoplasms |
| Neoplasms, Experimental Antibodies | >70 publications with RB and Neoplasms, Experimental |
| Osteosarcoma Antibodies | >64 publications with RB and Osteosarcoma |
| Drug Toxicity Antibodies | >59 publications with RB and Drug Toxicity |
| Liver Diseases Antibodies | >48 publications with RB and Liver Diseases |
Organs/Tissues associated with RB blocking peptide
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Blood Antibodies | >251 publications with RB and Blood |
| Eye Antibodies | >207 publications with RB and Eye |
| Brain Antibodies | >173 publications with RB and Brain |
| Lung Antibodies | >112 publications with RB and Lung |
| Bone Antibodies | >91 publications with RB and Bone |
| Liver Antibodies | >87 publications with RB and Liver |
| Muscle Antibodies | >74 publications with RB and Muscle |
| Skin Antibodies | >50 publications with RB and Skin |
| Intestine Antibodies | >49 publications with RB and Intestine |
| Prostate Antibodies | >46 publications with RB and Prostate |